[{"orgOrder":0,"company":"Sebela Pharmaceuticals","sponsor":"BRAINTREE LABS","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Tegoprazan","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Sebela Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sebela Pharmaceuticals \/ SEBELA PHARMACEUTICALS INC","highestDevelopmentStatusID":"10","companyTruncated":"Sebela Pharmaceuticals \/ SEBELA PHARMACEUTICALS INC"},{"orgOrder":0,"company":"Sebela Pharmaceuticals","sponsor":"Destiny Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"NTCD-M3","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sebela Pharmaceuticals","amount2":0.56999999999999995,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.56999999999999995,"dosageForm":"Liquid","sponsorNew":"Sebela Pharmaceuticals \/ Sebela Pharmaceuticals Inc","highestDevelopmentStatusID":"8","companyTruncated":"Sebela Pharmaceuticals \/ Sebela Pharmaceuticals Inc"}]

Find Clinical Drug Pipeline Developments & Deals by Sebela Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Under the terms of the deal, Sebela will lead the future clinical development and commercialisation activities of NTCD-M3 in North America. NTCD-M3 is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. di...

                          Brand Name : NTCD-M3

                          Molecule Type : Large molecule

                          Upfront Cash : $1.0 million

                          February 24, 2023

                          Lead Product(s) : NTCD-M3

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : Destiny Pharma

                          Deal Size : $570.0 million

                          Deal Type : Collaboration

                          blank

                          02

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Tegoprazan (CJ-12420) is a novel agent in development for the treatment of acid-related gastrointestinal diseases. Tegoprazan has already received marketing authorization in multiple territories, including South Korea and China.

                          Brand Name : CJ-12420

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 19, 2022

                          Lead Product(s) : Tegoprazan

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Recipient : BRAINTREE LABS

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank